Your Messages Inbox
Most Viewed Abstracts
1. Report Shows Shift in Starting Salaries for Physicians 2. 2008 Exclusive Survey—Earnings: Good news for primary care income 3. Medicare pay-for-reporting effort draws fire from frustrated doctors 4. Debunking Myths in the US Healthcare System 5. Statins and cancer risk
Your Article Summary
See Latest ArticlesDuration of Pharmacotherapy with Long-Acting Injectable Risperidone in the Treatment of Schizophrenia
Psychiatric Quarterly, 09/23/09
Mohamed S et al. – Less than half of patients on LAIR continued treatment for 18 months, a smaller proportion than of those started on most oral first– or second–generation antipsychotics, suggesting that for many patients with schizophrenia improved adherence from this treatment may not be sustained.
Related Articles
Auditory gating deficit to human voices in schizophrenia: A MEG study
Schizophrenia Research, 10/01/09
Relevance Score: 93%
Age at onset and cognition in schizophrenia: meta-analysis
British Journal of Psychiatry, 10/06/09
Relevance Score: 92%
Beyond symptom dimensions: Schizophrenia risk factors for patient groups derived by latent class analysis
Schizophrenia Research, 10/30/09
Relevance Score: 91%
Functional Magnetic Resonance Imaging of Inner Speech in Schizophrenia
Biological Psychiatry, 10/26/09
Relevance Score: 91%
Sensory Processing in Schizophrenia: Neither Simple nor Intact
Schizophrenia Bulletin, 10/19/09
Relevance Score: 91%
Today in Neuro/Psych pharmacology...keeping you current
Receive free subspecialty "5-minute updates" via email
Central Levodopa Influx and the Clinical Motor Response to Levodopa in Patients With Parkinson Disease Complicated With Motor Fluctuations and Dyskinesias
Clinical Neuropharmacology, 12/08/09
Levodopa-Induced Dyskinesias in Parkinson Disease Are Independent of the Extent of Striatal Dopaminergic Denervation: A Pharmacological and SPECT Study
Clinical Neuropharmacology, 12/08/09
Rapid Enhancement of Glutamatergic Neurotransmission in Bipolar Depression Following Treatment with Riluzole
Neuropsychopharmacology, 12/08/09
Sponsor
Article Search
Sponsor